This post is principally addressed to academics in the UK, though some of it may apply to people in other countries too. The current deal that the universities have with Elsevier expires at the end of this year, and a new one has been negotiated between Elsevier and Jisc Collections, the body tasked with representing the UK universities. If you want, you can read a thoroughly misleading statement about it on Elsevier’s website. On Jisc’s website is a brief news item with a link to further details that tells you almost nothing and then contains a further link entitled “Read the full description here”, which appears to be broken. On the page with that link can be found the statement
The ScienceDirect agreement provides access to around 1,850 full text scientific, technical and medical (STM) journals – managed by renowned editors, written by respected authors and read by researchers from around the globe – all available in one place: ScienceDirect. Elsevier’s full text collection covers titles from the core scientific literature including high impact factor titles such as The Lancet, Cell and Tetrahedron.
Unless things have changed, this too is highly misleading, since up to now most Cell Press titles have not been part of the Big Deal but instead are part of a separate package. This point is worth stressing, since failure to appreciate it may cause some people to overestimate how much they rely on the Big Deal — in Cambridge at least, the Cell Press journals account for a significant percentage of our total downloads. (To be more precise, the top ten Elsevier journals accessed by Cambridge are, in order, Cell, Neuron, Current Biology, Molecular Cell, The Lancet, Developmental Cell, NeuroImage, Cell Stem Cell, Journal of Molecular Biology, and Earth and Planetary Science Letters. Of those, Cell, Neuron, Current Biology, Molecular Cell, Developmental Cell and Cell Stem Cell are Cell Press journals, and they account for over 10% of all our access to Elsevier journals.)